Monday, August 28, 2000
The concept of a platelet pathogen inactivation system seems
simple - kill viruses, bacteria and leukocytes while leaving platelet function
and number intact. Cerus Corp.'s European Phase III trial of its Intercept pathogen
inactivation system missed some of its primary end points related to platelet
counts. But the company believes it knows why, and believes the results won't
hinder European marketing approval.
CERS and partner Baxter Healthcare Corp. (BAX, Deerfield, Ill.)
thus do not expect to wait for results from their ongoing 600-patient U.S. Phase
III trial before making a European regulatory submission by year end.